In addition, mutations in the AR ligand-binding domain, along with genetic structural rearrangements, have been implicated in the dysregulation of AR signaling, leading to the development of PC disease subtypes: hormone-sensitive PC and metastatic castration-resistant prostate cancer (mCRPC), suggesting AR mutations may serve as biomarkers predicting sensitivity to AR-related targeted therapies [74,76]. Here, AR is linked to pachyonychia congenita.